The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history of the reported lot did not indicate a lot specific quality issue.The investigation was unable to determine a conclusive cause for the reported material deformation.Additionally, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.The reported patient effects of angina and obstruction are listed in the xience skypoint everolimus eluting coronary stent systems instructions for use as a known patient effects of coronary stenting procedures.There is no indication of a product quality issue with respect to manufacture, design, or labeling.
|
It was reported that on (b)(6) 2022, the 3.5x48mm xience skypoint stent was implanted.However, on (b)(6) 2022, the patient was re-hospitalized as the patient experienced chest pain.Angiogram confirmed an obstruction at mid-stent, which is believed the stent collapsed at midpoint.Unspecified guide wires were attempted to be advance; however, could not cross.Therefore, the patient was referred to a different hospital for treatment.There were no clinically significant delay reported.No additional information was provided.
|